FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity (Q38070075)

28 August 2017

1 reference

title

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity (English)

1 reference

28 August 2017

1 reference

Krishna S Gunturu

1

1 reference

28 August 2017

Xiaopan Yao

2

1 reference

28 August 2017

Xiangyu Cong

3

1 reference

28 August 2017

Jaykumar R Thumar

4

1 reference

28 August 2017

Howard S Hochster

5

1 reference

28 August 2017

Stacey M Stein

6

1 reference

28 August 2017

Jill Lacy

7

1 reference

28 August 2017

publication date

28 December 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

30

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

361

1 reference

28 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Irinotecan chemotherapy associated with transient dysarthria and aphasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Irinotecan-induced dysarthria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0361-2

Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer

21 January 2018

1 reference

12 December 2020

Hypoglossal and phrenic responses to cholinergic agents applied to ventral medullary surface.

1 reference

12 December 2020

Irinotecan-induced dysarthria

1 reference

12 December 2020

Irinotecan-induced central nervous system toxicity: a case report

1 reference

12 December 2020

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

12 December 2020

10.1007/S12032-012-0361-2

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1041672338

0 references

1 reference